Seski J C, Edwards C L, Copeland L J, Gershenson D M
Obstet Gynecol. 1981 Sep;58(3):361-3.
To evaluate the role of hexamethylmelamine (HMM) in the treatment of endometrial cancer, 20 women with metastatic or recurrent endometrial carcinoma received HMM orally at a dose of 8 mg/kg/day. Six patients (30%) showed a partial response, with a median duration of response of 3.5 months and a range of 1 to 7 months. Two patients responded to HMM as a second-line agent following previous treatment with nonhormonal chemotherapy. There were no complete responses. The major toxicities noted with HMM therapy were nausea, vomiting, and neurotoxicity. In 6 patients (30%), therapy with HMM was discontinued because of toxicity. Although HMM is active against endometrial cancer when given at a dose of 8 mg/kg/day, it appears to have limited usefulness because toxicity precludes its prolonged administration.
为评估六甲蜜胺（HMM）在子宫内膜癌治疗中的作用，20例转移性或复发性子宫内膜癌患者口服HMM，剂量为8mg/kg/天。6例患者（30%）出现部分缓解，缓解持续时间中位数为3.5个月，范围为1至7个月。2例患者在先前接受非激素化疗后，作为二线药物对HMM有反应。无完全缓解病例。HMM治疗中观察到的主要毒性为恶心、呕吐和神经毒性。6例患者（30%）因毒性而停止HMM治疗。虽然HMM以8mg/kg/天的剂量给药时对子宫内膜癌有活性，但由于毒性妨碍其长期给药，其作用似乎有限。
